

Durvalumab (anti-PD-L1)

Cat. No.:	HY-P9919A
CAS No.:	1428935-60-7
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody ^[1] . Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC ₅₀ are 0.1 and 0.04 nM ^[1] respectively ^{[1][2]} .
IC ₅₀ & Target	IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80) ^[2]

CUSTOMER VALIDATION

- Cancer Discov. 2020 Dec;10(12):1872-1893.
- Cell Rep. 2022 Feb 8;38(6):110349.
- Research Square Print. 2022 Aug.
- Preprints. 10 May 2022.
- Patent. US20200253884A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.
- [2]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA